Discover the research Description BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein
Clinical candidates such as Roches Trontinemab (a TfR1-bispecific derivative of Gantenerumab) show rapid amyloid clearance and reduced amyloid-related imaging abnormalities (ARIA), reflecting improved distribution
1):S21S31
There is an epidemic deficiency of glutathione in patients today
The German BfArM and equivalent agencies (ANSM in France, AEMPS in Spain, AIFA in Italy, URPL in Poland) treat unauthorized human use of these compounds as outside the scope of the marketing authorization regime entirely
Furthermore, alignment analysis also demonstrated that Asn (N), Gly (G), Arg (R), Pro (P), Thr (T), Tyr (Y), Lys (K), Ala-Ser (AS), Cys-Gly (CG), Phe-Pro (FP), Glu-Pro (EP), Leu-Lys (LK), Lys-Phe (KF), Asn-Gly (NG), Asn-Gln-Phe (NQF), and Trp-Asn-Phe (WNF) residues were strictly conserved in all aligned sequences, indicating their potential functions in enzyme activity and/or stability (Supplementary Figure S3)